Stock RARE ULTRAGENYX PHARMACEUTICAL INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Ultragenyx Pharmaceutical Inc.

Equities

RARE

US90400D1081

Real-time Estimate Cboe BZX
Other stock markets
 02:28:01 2024-04-26 pm EDT 		5-day change 1st Jan Change
44.3 USD +1.01% Intraday chart for Ultragenyx Pharmaceutical Inc. +4.72% -7.21%
Apr. 22 RBC Starts Ultragenyx Pharmaceutical at Outperform, Speculative Risk With $77 Price Target, Sees 'Particularly Attractive' Risk/Reward MT
Apr. 15 Health Care Ticks Down Amid Rotation From Rate-Sensitive Sectors -- Health Care Roundup DJ

Evolution of the average Target Price on Ultragenyx Pharmaceutical Inc.

Price target over the last 5 years

History of analyst recommendation changes

3df691babb48fcbe0b626.tLIK1wvalFPXKwZKolnkGJiQBAgGiwjaOClciAVLrxY.g-I8uSbq-gm9GkN51DfTSeKgVyUywUmgQHMf20MJlmDg6lOfQKvhZZxeXw~90ff107e6b4b23924aa1692ed9a976c2

Analyst Recommendations on Ultragenyx Pharmaceutical Inc.

RBC Starts Ultragenyx Pharmaceutical at Outperform, Speculative Risk With $77 Price Target, Sees 'Particularly Attractive' Risk/Reward MT
JPMorgan Adjusts Price Target on Ultragenyx Pharmaceutical to $92 From $88, Maintains Overweight Rating MT
Canaccord Genuity Adjusts Ultragenyx Pharmaceutical's Price Target to $111 From $110, Keeps Buy Rating MT
Wedbush Lifts Ultragenyx Pharmaceutical's PT to $48 From $47, Notes Fuller Catalyst Lineup for 2024; Keeps Neutral Rating MT
Wedbush Raises Ultragenyx Pharmaceutical's PT to $47 From $43, Updates Model After Pre-Announced Full-Year 2023 Figures, Increases Forward Trajectory on Crysvita; Maintains Neutral Rating MT
Wells Fargo Initiates Ultragenyx Pharmaceutical With Overweight Rating, Price Target is $72 MT
JPMorgan Adjusts Ultragenyx Pharmaceutical Price Target to $74 From $76, Maintains Overweight Rating MT
Morgan Stanley Adjusts Price Target on Ultragenyx Pharmaceutical to $84 From $90, Maintains Overweight Rating MT
Wedbush Cuts Price Target on Ultragenyx Pharmaceutical to $43 From $47, Maintains Neutral Rating MT
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI) CI
Morgan Stanley Cuts Ultragenyx Pharmaceutical's Price Target to $90 From $95, Keeps Overweight Rating MT
Wedbush Trims Ultragenyx Pharmaceutical's PT to $47 From $49, Keeps Neutral Rating MT
Citigroup Adjusts Ultragenyx Pharmaceutical Price Target to $133 From $130, Maintains Buy Rating MT
Evercore ISI Upgrades Ultragenyx Pharmaceutical to Outperform From In Line, Raises Price Target to $80 From $60 MT
Wedbush Raises Ultragenyx Pharmaceutical's Price Target to $51 From $48, Keeps Neutral Rating MT
Wedbush Lifts Ultragenyx Pharmaceutical's Price Target to $48 From $47, Keeps Neutral Rating MT
Cantor Fitzgerald Initiates Ultragenyx Pharmaceutical at Overweight With $114 Price Target MT
Baird Adjusts Price Target on Ultragenyx Pharmaceutical to $57 From $50, Maintains Outperform Rating MT
Wedbush Trims Price Target on Ultragenyx Pharmaceutical to $47 From $48, Maintains Neutral Rating MT
Canaccord Genuity Assumes Coverage on Ultragenyx Pharmaceutical With Buy Rating, $90 Price Target MT
HC Wainwright Assumes Ultragenyx With Buy Rating, $82 Price Target MT
Credit Suisse Adjusts Ultragenyx Pharmaceutical's Price Target to $96 From $105, Keeps Outperform Rating MT
Baird Upgrades Ultragenyx Pharmaceutical to Outperform From Neutral, Adjusts Price Target to $50 From $63 MT
Wedbush Lowers Ultragenyx Pharmaceutical's PT to $49 From $51, Says Waiting for Additional Visibility Into Clinical Programs; Keeps Neutral Rating MT
Wedbush Cuts Price Target on Ultragenyx Pharmaceutical to $51 From $68, Maintains Neutral Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
43.85 USD
Average target price
89.52 USD
Spread / Average Target
+104.16%
High Price Target
140 USD
Spread / Highest target
+219.27%
Low Price Target
48 USD
Spread / Lowest Target
+9.46%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Ultragenyx Pharmaceutical Inc.

RBC Capital Markets
JPMorgan Chase
Canaccord Genuity
Wedbush
Wells Fargo Securities
Morgan Stanley
Citigroup
Evercore ISI
Cantor Fitzgerald
Baird
HC Wainwright
Credit Suisse
Guggenheim
Goldman Sachs
Piper Sandler
Stifel Nicolaus
SVB Leerink
UBS
Barclays
BofA Securities
J.P. Morgan Chase

Ratings for Ultragenyx Pharmaceutical Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. RARE Stock
  4. Consensus Ultragenyx Pharmaceutical Inc.